Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

Masahide Kondo; Shu-Ling Hoshi; Masakazu Toi

doi:10.1093/jjco/hyp081

Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

Jpn J Clin Oncol. 2009 Nov;39(11):767-70. doi: 10.1093/jjco/hyp081. Epub 2009 Aug 5.

Authors

Masahide Kondo¹, Shu-Ling Hoshi, Masakazu Toi

Affiliation

¹ Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan. [email protected]

PMID: 19656807
DOI: 10.1093/jjco/hyp081

Abstract

'Cost saving' was suggested in our recent economic evaluation of chemoprevention of breast cancer targeting women at high risk in Japan. However, this budget impact analysis reveals that the introduction of chemoprevention appears to be not budget saving for approximately 20 years, whereas the level of budget impact seems affordable.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Anticarcinogenic Agents / economics
Anticarcinogenic Agents / therapeutic use*
Breast Neoplasms / economics*
Breast Neoplasms / prevention & control*
Chemoprevention / economics
Chemoprevention / methods
Cost-Benefit Analysis
Drug Costs*
Estrogen Receptor Modulators / economics
Estrogen Receptor Modulators / therapeutic use*
Evidence-Based Medicine
Female
Humans
Japan
Middle Aged
Primary Prevention / economics
Primary Prevention / methods
Raloxifene Hydrochloride / economics
Raloxifene Hydrochloride / therapeutic use*
Risk Assessment
Risk Factors
Tamoxifen / economics
Tamoxifen / therapeutic use*

Substances

Anticarcinogenic Agents
Estrogen Receptor Modulators
Tamoxifen
Raloxifene Hydrochloride